# A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants

> **NCT07528703** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Nanjing Reju Therapeutics Co., Ltd** · enrollment: 42 (estimated)

## Conditions studied

- IPF

## Interventions

- **DRUG:** RC010 Inhalation Powder
- **DRUG:** RC010 Inhalation Powder placebo

## Key facts

- **NCT ID:** NCT07528703
- **Lead sponsor:** Nanjing Reju Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-04
- **Final completion:** 2027-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07528703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07528703, "A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07528703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*